|
|
5-day change | 1st Jan Change | ||
|
2.085 USD |
-1.65% | -10.90% | -26.33% | |
Published on 06/17/2025 at 16:05
Presentation Operator Message
Operator (Operator)
Ladies and gentlemen, thank you for standing by. My name is Jay, and I will be your conference operator today. At this time, I would like to welcome
I
|
Skye Bioscience, Inc., Q1 2025 Earnings Call, May 08, 2025 |
04:05pm |
|
|
Skye Bioscience, Inc. Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab |
May. 19 |
CI |
|
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) |
May. 13 |
RE |
|
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral Cb1 Inhibition for Weight Loss Presented At European Congress on Obesity |
May. 13 |
CI |
|
Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 08 |
CI |
|
Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model |
Apr. 15 |
RE |
|
Skye Bioscience, Inc. Announces New Preclinical Data for its Novel CB1 Antibody, Nimacimab |
Apr. 15 |
CI |
|
Skye Bioscience Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Business Update |
Mar. 20 |
RE |
|
Skye Bioscience, Inc., Q4 2024 Earnings Call, Mar 20, 2025 |
Mar. 20 |
|
|
Skye Bioscience, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
Mar. 20 |
CI |
|
Skye Bioscience, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-16-2025 10:30 AM |
Jan. 16 |
|
|
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated Cb1 Inhibitor |
Nov. 14 |
CI |
|
Skye Bioscience, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 12:30 PM |
Nov. 13 |
|
|
Skye Bioscience, Inc., Q3 2024 Earnings Call, Nov 07, 2024 |
Nov. 07 |
|
|
Skye Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 07 |
CI |
|
Skye Bioscience Demonstrates Prominent Role of Peripheral Cb1 Inhibition and Achieves Significant Weight Loss with Novel Cb1-Inhibiting Antibody, Nimacimab, in Preclinical Model |
Nov. 04 |
CI |
|
Skye Bioscience Names Paul Grayson as Chairman of the Board |
24-10-29 |
CI |
|
Skye Bioscience, Inc.(NasdaqGM:SKYE) dropped from NASDAQ Transportation Index |
24-09-23 |
CI |
|
Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment |
24-09-23 |
DJ |
|
Skye Bioscience, Inc. Appoints Puneet S. Arora as Chief Medical Officer |
24-09-03 |
CI |
|
Skye Bioscience, Inc. Launches Phase 2 Cbeyond Clinical Trial of Its Differentiated Cb1 Inhibitor, Nimacimab, in Patients with Obesity |
24-08-22 |
CI |
|
Skye Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-09 |
CI |
|
Skye Bioscience, Inc. Announces Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints |
24-07-24 |
CI |
|
Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab |
24-07-11 |
CI |
|
Skye Bioscience, Inc. Announces Board and Committee Changes, Effective August 1, 2024 |
24-07-03 |
CI |
EMBI: Dynamic Chart
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
